Results 91 to 100 of about 76,887 (294)

Epidural and Intrathecal Opioids [PDF]

open access: yesAnaesthesia and Intensive Care, 1987
Small doses of epidural and intrathecal opioids produce effective and prolonged analgesia postoperatively, although the quality of analgesia does not differ from when conventional routes are used. The different opioids differ only in the speed of onset and duration of action, and in the incidence of side-effects.
openaire   +2 more sources

Effect of intrathecal dexmedetomidine on preventing shivering in cesarean section after spinal anesthesia: a meta-analysis and trial sequential analysis

open access: yes, 2018
Shuai Miao,* Mengzhu Shi,* Lan Zou, Guanglei Wang Department of Anesthesiology, The Affiliated Hospital of XuZhou Medical University, XuZhou, JiangSu, China *These authors contributed equally to this work Objective: Intrathecal dexmedetomidine (DEX ...
Shi M, Zou L, Miao S, Wang G
core  

Patients with intrathecal IgG synthesis and chronic inflammatory CNS disease.

open access: yes, 2023
Patients with intrathecal IgG synthesis and chronic inflammatory CNS disease.
Markus Kowarik (7867373)   +10 more
core   +1 more source

Blood SOD1 Activity in ALS Patients Receiving Tofersen Treatment

open access: yesAnnals of Neurology, EarlyView.
Objective The antisense oligonucleotide tofersen is the first disease‐modifying drug for SOD1‐related amyotrophic lateral sclerosis (ALS) and was approved because of its ability to reduce SOD1 protein and neurofilament levels. The effect of tofersen on SOD1 activity is unclear but of clinical relevance because homozygous SOD1 mutations, linked to ...
Katharina Goehring   +18 more
wiley   +1 more source

Switching disease‐modifying therapies in patients with spinal muscular atrophy: A systematic review on effectiveness outcomes

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
With multiple disease‐modifying therapies now available, treatment switching has become an important clinical consideration in the management of spinal muscular atrophy (SMA). While some switches are prompted by suboptimal clinical response, more commonly they are driven by treatment burden, convenience, or adverse events.
Andrej Belančić   +4 more
wiley   +1 more source

Evaluation of the effect of intrathecal clonidine to decrease shoulder tip pain in laparoscopy under spinal anaesthesia

open access: yesIndian Journal of Anaesthesia, 2010
Sixty ASA grade I/II patients scheduled for elective short laparoscopic procedures under spinal anaesthesia were divided into two groups of 30 each. The first group (group C) received 3.5 ml of hyperbaric bupivacaine with 30 mcg of clonidine.
Poonam S Ghodki   +2 more
doaj   +1 more source

Optimization of pharmaceutical research and development by early‐phase assessment of investigational medicinal products

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Small and mid‐sized pharmaceutical innovators often have limited in‐house health economics and market access expertise, and may struggle to align development strategies of investigational medicinal products with health system needs and payer expectations.
Zoltán Kaló   +5 more
wiley   +1 more source

The Configuration of the Perivascular System Transporting Macromolecules in the CNS

open access: yesFrontiers in Neuroscience, 2019
Large blood vessels entering the CNS are surrounded by perivascular spaces that communicate with the cerebrospinal fluid and, at their termini, with the interstitial space.
Beata Durcanova   +12 more
doaj   +1 more source

The schematic presentation of intrathecal catheter placement.

open access: yes, 2015
A–C7 –Th1 level of spinal cord, B–intrathecal catheter, C–a place of surgery.
Greg J. Stanisz (825738)   +10 more
core   +1 more source

Cost‐utility analysis of nusinersen–risdiplam switch in patients with spinal muscular atrophy in Croatia: A discrete event simulation model

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Introduction In recent years, the treatment of spinal muscular atrophy (SMA), a rare disease, has significantly progressed, improving patients' survival and overall quality of life. However, current SMA treatments are expensive, and some (nusinersen) are very inconvenient for patients.
Andrej Belančić   +4 more
wiley   +1 more source

Home - About - Disclaimer - Privacy